Stay ahead with our exclusive monthly bulletins, designed specifically for legal professionals. Each issue delivers concise updates, clinical insights, and practical applications of ocular motor testing in personal injury cases.

February 2026 | ArkLaTex TBI

Every personal injury attorney knows the frustration. Your client suffered a clear traumatic brain injury: post-concussion symptoms persist, daily functioning deteriorates, life quality plummets. But opposing counsel pushes back hard because there's no pre-injury baseline test to prove the decline.

The insurance adjuster claims malingering. Defense experts dismiss subjective complaints. Your client's injury gets minimized to "just a bump on the head" that should have resolved months ago.

Without objective pre-injury data showing what your client's neurological function looked like before the accident, proving causation becomes an uphill battle. Or at least, that's what defense teams want you to believe.

Here's what most attorneys don't realize: baseline data is no longer required to establish objective neurological dysfunction from TBI.

Advanced eye-tracking technology now uses normative reference data: population-level benchmarks of healthy eye movement patterns across different age groups. This FDA-cleared approach provides the objective comparison point your case needs, regardless of whether your client ever took a pre-injury test.

Think of normative data as a comprehensive database of what "normal" looks like. Researchers compiled eye movement measurements from thousands of healthy individuals, establishing precise ranges for expected performance based on age and demographics. When your client's eye-tracking results fall significantly outside these established norms, it demonstrates measurable neurological disruption: quantifiable evidence that holds up under cross-examination.

The clinical validation is substantial. Studies show eye-tracking technology detects abnormal eye movements in up to 90% of patients with mild traumatic brain injury. These aren't subjective symptom reports. These are objective, measurable deviations from established healthy function.

The connection between eye movements and brain function runs deeper than most people realize. Ocular motor control requires precise coordination across multiple brain regions: the brainstem, cerebellum, frontal cortex, and various neural pathways that integrate visual, vestibular, and motor systems.

When traumatic brain injury disrupts these systems, even subtly, eye movements reveal the dysfunction. Patients demonstrate abnormal horizontal, vertical, or torsional eye movements. Tracking becomes inconsistent. Smooth pursuit degrades. Reaction times slow. These deficits appear measurable and quantifiable through specialized ocular motor testing.

Traditional concussion assessments rely heavily on self-reported symptoms and subjective clinical observations. Your client tells the doctor about headaches, dizziness, concentration problems. The physician performs basic neurological checks. All valuable information, certainly, but easily challenged by defense teams as subjective or exaggerated.

Eye-tracking technology removes that vulnerability. The measurements are objective. The algorithms detect microscopic deviations invisible to the naked eye. The results provide hard numbers that either fall within normal ranges or don't. There's no room for interpretation or debate about effort level.

FDA clearance matters significantly for litigation purposes. The normative database and testing protocols underwent rigorous review and received FDA clearance for clinical use in diagnosing and managing mild traumatic brain injury.

This regulatory validation strengthens admissibility arguments substantially. When opposing counsel challenges your expert's methodology, you can point to FDA clearance as evidence of scientific validity and reliability. The technology met stringent federal standards for safety and effectiveness. Courts recognize FDA approval as a meaningful indicator of scientific acceptance within the relevant medical community.

Defense teams often attack new diagnostic technologies as experimental or unproven. FDA clearance neutralizes that attack. The testing method already passed the threshold for clinical use in diagnosing the exact condition at issue in your case.

Additionally, the normative data approach addresses Daubert challenges more effectively than individual baseline comparisons. The reference database includes thousands of subjects, providing statistical power and population representation that single-subject baselines cannot match. The methodology follows established scientific principles. The error rates are quantifiable. The standards for measurement are documented and maintained consistently.

One of the most powerful aspects of normative data: timing becomes less critical than with traditional baseline-comparison testing.

Many TBI cases don't reach an attorney's desk until months or even years after the injury. By that point, the acute symptoms may have evolved into persistent post-concussion syndrome. Traditional testing approaches struggle at this stage because they require testing soon after injury to be most effective.

Normative eye-tracking testing remains valid regardless of when it's administered. Whether your client gets tested three months post-injury or three years post-injury, the results compare against the same age-appropriate normative standards. If abnormal eye movements persist years later, that actually strengthens your damages claim by demonstrating lasting neurological impact.

Research supports this extended utility. Studies show particular eye-tracking metrics differentiate mild, moderate, and severe TBI cases, suggesting the measurements remain sensitive to injury severity long past the acute phase. Chronic deficits show up in the data.

This extended window provides crucial flexibility in case development. When clients come to you with old injuries, you can still obtain objective diagnostic evidence. When defendants argue the injury should have resolved by now, you can prove it hasn't: with quantifiable measurements that don't rely on your client's symptom reports.

Normative eye-tracking data strengthens multiple aspects of TBI litigation strategy.

Establishing Causation: When defendants argue pre-existing conditions or alternative causes, objective testing that shows clear deviation from healthy norms supports injury causation. The testing identifies specific patterns of dysfunction consistent with traumatic brain injury rather than other conditions.

Quantifying Severity: Eye-tracking results provide gradation. Results don't just show "injured" versus "not injured": they demonstrate how far outside normal ranges your client falls. More severe deviations support higher damage valuations.

Documenting Persistence: Follow-up testing at different time points creates an objective record of ongoing impairment. When symptoms persist but defendants claim resolution, repeated eye-tracking tests provide quantifiable evidence of continued dysfunction.

Rebutting Malingering Claims: Sophisticated eye-tracking algorithms detect effort and consistency. The testing produces results that would be virtually impossible to fake convincingly. Defendants lose their favorite argument that your client is exaggerating symptoms.

Supporting Expert Testimony: Your medical experts can reference FDA-cleared testing, established normative databases, and peer-reviewed research when explaining how the diagnosis was reached. The scientific foundation is solid.

Strengthening Settlement Negotiations: Objective test results that clearly show abnormal function shift settlement dynamics. Insurance adjusters can't dismiss hard data as easily as symptom complaints. The case value increases when you can prove injury definitively.

The technology tracks multiple aspects of eye movement during various tasks. Patients might follow moving targets, shift their gaze between points, or maintain focus while their head moves. The system records eye position hundreds of times per second, capturing minute details of movement accuracy, velocity, latency, and coordination.

The algorithms then compare these measurements against normative reference ranges established for the patient's age group. Results identify specific deficits: perhaps smooth pursuit shows irregular velocity, or saccadic eye movements demonstrate prolonged latency, or convergence reveals inadequate precision.

Each measurement provides independent evidence of neurological dysfunction. The testing examines horizontal eye movements, vertical eye movements, and torsional eye movements separately. Multiple metrics showing abnormality create a comprehensive picture of impairment that's difficult for defense experts to explain away.

The approach is quantitative, repeatable, and standardized. Different examiners testing the same patient should generate consistent results because the technology removes examiner subjectivity from the measurement process.

The absence of pre-injury baseline testing no longer weakens your TBI case. FDA-cleared eye-tracking technology using normative reference data provides the objective comparison standard you need, regardless of when your client's injury occurred.

For personal injury attorneys handling TBI cases, this represents a significant advancement in available evidence. You can now obtain quantifiable, court-admissible diagnostic evidence even when clients had no pre-injury testing. The science is established. The regulatory approval is secured. The methodology withstands legal scrutiny.

Your client's injury deserves proper documentation and fair compensation. Objective testing that reveals measurable neurological dysfunction makes that goal substantially more achievable.